 |
More: Digestive Disease Week (DDW) 2008 DDW 2008: Functional Gastrointestinal Disorders CME May 17 - 22, 2008, San Diego, California Author Information and Disclosures This activity is not sanctioned by, nor a part of, Digestive Disease Week. Conference news does not receive grant support and is produced independently.
Release Date: June 30, 2008; Valid for credit through June 30, 2009 | Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of Digestive Disease Week. These materials and the related activity are not sanctioned by Digestive Disease Week or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review current concepts underlying the pathophysiology, diagnosis, and management of upper GI motility disorders, including functional dyspepsia and gastroparesis
- Review current concepts underlying the pathophysiology, diagnosis, and
management of functional bowel disorders (irritable bowel syndrome, chronic constipation) as well as the impact of these disorders on the healthcare system and patient alike
Authors and Disclosures Nicholas J. Talley, MD, PhD, FACP, FRACP, FRC
Disclosure: Nicholas J. Talley, MD, PhD, FACP, FRACP, FRC, has disclosed that he has served
as a consultant to AccreditEd, Addex Pharmaceuticals SA, Annenberg Center, Astellas Pharma, Inc. US, AstraZeneca R&D - Lund, Axcan Pharma, Callisto Pharmaceuticals, Conexus, Dynogen, F-Network, Ferring Pharmaceuticals, Inc., Interactive Forum, Inc., McNeil Consumer, Medscape from WebMD, Metabolic Pharma, MGI Pharma, Microbia, Inc., Novartis, Oakstone Publishing, Optum HC, Procter & Gamble, and Salix. Dr. Talley has also disclosed that he has received financial support
from Dynogen, GlaxoSmithKline, Novartis, Takeda, and Tioga. Brian E. Lacy, MD, PhD
Disclosure: Brian E. Lacy, MD, PhD, has disclosed that he has received grants for investigator-initiated research from Prometheus, Medtronic, and Novartis, and that he has served on the speaker's bureaus of Novartis and Takeda. Maria L. Gaiso, PhD
Disclosure: Maria L. Gaiso, PhD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
